Royal Bank Of Canada Apellis Pharmaceuticals, Inc. Transaction History

Royal Bank Of Canada

$471 Billion
Q3 2024

A detailed history of Royal Bank Of Canada transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 141,995 shares of APLS stock, worth $4.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

141,995

Previous 132,961 6.79%

Holding current value

$4.05 Million

Previous $5.1 Million 19.71%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$28.84 - $41.15 $260,540 - $371,749	9,034 Added 6.79%	141,995 $4.1 Million
Q2 2024 Aug 14, 2024	BUY	$38.07 - $59.71 $1.2 Million - $1.89 Million	31,627 Added 31.21%	132,961 $5.1 Million
Q1 2024 Nov 05, 2024	SELL	$55.39 - $72.47 $1.75 Million - $2.29 Million	-31,627 Reduced 23.79%	101,334 $5.96 Million
Q1 2024 May 15, 2024	SELL	$55.39 - $72.47 $901,527 - $1.18 Million	-16,276 Reduced 13.84%	101,334 $5.96 Million
Q4 2023 Feb 14, 2024	SELL	$37.14 - $64.82 $39,145 - $68,320	-1,054 Reduced 0.89%	117,610 $7.04 Million
Q3 2023 Nov 14, 2023	SELL	$23.65 - $89.22 $516,066 - $1.95 Million	-21,821 Reduced 15.53%	118,664 $4.51 Million
Q2 2023 Aug 14, 2023	BUY	$76.68 - $93.31 $248,596 - $302,511	3,242 Added 2.36%	140,485 $12.8 Million
Q1 2023 May 15, 2023	BUY	$46.59 - $66.96 $1.58 Million - $2.27 Million	33,927 Added 32.84%	137,243 $9.05 Million
Q4 2022 Feb 14, 2023	BUY	$43.24 - $61.04 $1.26 Million - $1.78 Million	29,097 Added 39.2%	103,316 $5.34 Million
Q3 2022 Nov 14, 2022	SELL	$44.76 - $69.66 $355,976 - $554,005	-7,953 Reduced 9.68%	74,219 $5.07 Million
Q2 2022 Aug 15, 2022	SELL	$35.07 - $59.21 $266,882 - $450,588	-7,610 Reduced 8.48%	82,172 $3.72 Million
Q1 2022 May 16, 2022	SELL	$35.46 - $54.12 $546,367 - $833,880	-15,408 Reduced 14.65%	89,782 $4.56 Million
Q4 2021 Feb 14, 2022	BUY	$30.74 - $49.16 $409,118 - $654,270	13,309 Added 14.49%	105,190 $4.97 Million
Q3 2021 Nov 15, 2021	BUY	$31.4 - $69.84 $195,684 - $435,242	6,232 Added 7.28%	91,881 $3.03 Million
Q2 2021 Aug 16, 2021	BUY	$40.9 - $64.9 $3.5 Million - $5.56 Million	85,649 New	85,649 $5.41 Million

Others Institutions Holding APLS

# of Institutions

301

Shares Held

112M

Call Options Held

3.85M

Put Options Held

1.09M

View Full List

About Apellis Pharmaceuticals, Inc.

Ticker APLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 109,865,000
Market Cap $3.13B
Description
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...

More about APLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Apellis Pharmaceuticals, Inc. Transaction History